Draft:John Oyler
| Submission declined on 14 June 2024 by SafariScribe (talk). This submission is not adequately supported by reliable sources. Reliable sources are required so that information can be verified. If you need help with referencing, please see Referencing for beginners and Citing sources. This submission's references do not show that the subject qualifies for a Wikipedia article—that is, they do not show significant coverage (not just passing mentions) about the subject in published, reliable, secondary sources that are independent of the subject (see the guidelines on the notability of people). Before any resubmission, additional references meeting these criteria should be added (see technical help and learn about mistakes to avoid when addressing this issue). If no additional references exist, the subject is not suitable for Wikipedia.
Where to get help
How to improve a draft
You can also browse Wikipedia:Featured articles and Wikipedia:Good articles to find examples of Wikipedia's best writing on topics similar to your proposed article. Improving your odds of a speedy review To improve your odds of a faster review, tag your draft with relevant WikiProject tags using the button below. This will let reviewers know a new draft has been submitted in their area of interest. For instance, if you wrote about a female astronomer, you would want to add the Biography, Astronomy, and Women scientists tags. Editor resources
|  |
Comment: The sources aren't significant coverage to meet GNG. I would love to see more but if in any case, can be a redirect to BeiGene. Safari ScribeEdits! Talk! 23:26, 14 June 2024 (UTC)
John Oyler | |
|---|---|
| Born | 1967 or 1968 (age 56–57)[1] |
| Alma mater | Massachusetts Institute of Technology |
| Occupation | CEO of BeiGene |
| Board member of | Biotechnology Innovation Organization |
John V. Oyler is the CEO, chairman, and co-founder of global biotechnology company BeiGene.[2] Before founding BeiGene in 2010, he was co-founder and CEO at BioDuro and a leader at various other start-ups.
Education and early career
[edit]Oyler grew up in Pittsburgh, Pennsylvania.[1] He attended the Massachusetts Institute of Technology, where he started his first business renting and selling items to fellow students.[3] He graduated with a degree in mechanical engineering[2] in 1990.[4] He began his career as a consultant at McKinsey & Company, a role that involved travel to China and led him to develop an interest in the biopharmaceutical industry.[5] During his time at McKinsey, he earned an MBA degree from Stanford University and continued to work there after graduate school.[2]
Oyler joined Genta, a biotechnology company focused on cancer drugs, in 1997. At Genta, Oyler hired new management and grew the company's valuation from a few million dollars to $1.7 billion.[6]
In 1998,[7] Oyler was a founder of Telephia, a telecom research company[5] where he served as president.[8] Nielsen Holdings acquired Telephia, at the time a leading provider of research on consumer mobile phone use, in 2007.[9] Oyler was also CEO of Galenea, a company focused on treatments for psychiatric diseases,[10] from 2002 to 2004.[11]
In 2005, Oyler returned to China[5] and co-founded BioDuro, a contract research organization.[10] Oyler served as CEO, and the co-founders also provided all initial financing for the firm.[6] PPD acquired BioDuro in 2009.[12]
BeiGene
[edit]Oyler co-founded BeiGene in 2010 with Dr. Xiaodong Wang,[13] whom Oyler met while working at BioDuro.[2] Oyler and Wang provided part of the startup funding for the business,[13] including $10 million in capital from Oyler. Oyler is the company's Chairman and CEO.[2]
Under his leadership, BeiGene developed and marketed two cancer medicines: Tevimbra, a checkpoint inhibitor, and Brukinsa, a Bruton's tyrosine kinase inhibitor. Oyler and Wang envisioned a company that could produce affordable cancer medicines, so Oyler has focused on building up BeiGene's internal research capabilities to reduce clinical trial costs. The company has built up the capacity to run clinical trials in several regions simultaneously,[3] providing larger numbers of patients with more diversity.[14]
Oyler has also built up the company's global presence without locating primary operations in only one country, emphasizing how online collaboration is key to the company's operations.[2] As of 2023, BeiGene had 10,000 employees.[15]
Oyler joined the board of the Biotechnology Innovation Organization in June 2019.[16] PharmaVoice named Oyler one of the top 100 pharmaceutical industry leaders of 2022.[17]
Personal life
[edit]Oyler is married and has one daughter.[14]
References
[edit]- ^ a b Dai, Sarah (16 October 2017). "CEO of China health care start-up works hard on cancer drugs pipeline". South China Morning Post. Retrieved 27 September 2023.
- ^ a b c d e f Wright, Rob (1 November 2019). "How — And Why — John Oyler Built BeiGene". Life Science Leader. Retrieved 26 September 2023.
- ^ a b Henderson, Lisa (29 March 2023). "A Vision of Affordability". PharmExec. Retrieved 27 September 2023.
- ^ "Fireside chat with John Oyler". MIT Club of Hong Kong. Retrieved 27 September 2023.
- ^ a b c Saionz, Amanda (4 May 2023). "In Profile: BeiGene's John Oyler". PharmaBoardroom. Retrieved 26 September 2023.
- ^ a b Tremblay, Jean-François (2008). "China's Pharma Leaps Into Discovery" (PDF). Chemical & Engineering News. Retrieved 26 September 2023.
- ^ Gregson, Reily (30 November 1999). "Telephia Hopes to Become the A.C. Nielsen of Wireless World". RCR Wireless News. Retrieved 26 September 2023.
- ^ Gregson, Reily (30 November 1999). "Telephia expands into untethered Internet access monitoring". RCR Wireless News. Retrieved 26 September 2023.
- ^ Learmonth, Michael (28 June 2007). "Nielsen nabs Telephia". Variety. Retrieved 18 December 2023.
- ^ a b Jia, Hepeng (19 May 2008). "China's one stop research shop". Chemistry World. Retrieved 26 September 2023.
- ^ "John V. Oyler". The Medicine Maker. 2022. Retrieved 27 September 2023.
- ^ "PPD Buys BioDuro For $77 Million". Manufacturing.net. Associated Press. 30 November 2009. Retrieved 26 September 2023.
- ^ a b Loo, Daryl (2011-07-07). "BeiGene Brings Biotech to China". Bloomberg. Retrieved 2020-08-04.
- ^ a b Zhang Liang (11 September 2023). "抗癌新势力：百济神州的颠覆与创新". Harvard Business Review China. Retrieved 27 November 2023.
- ^ "Form 10-Q". BeiGene. 30 June 2023. Retrieved 15 August 2023.
- ^ "The Top 25 Healthcare Technology CEOs of Asia for 2020". The Healthcare Technology Report. 16 November 2020. Retrieved 27 September 2023.
- ^ Parrish, Meagan (6 September 2022). "Entrepreneurs: John Oyler". PharmaVoice. Retrieved 26 September 2023.
External links
[edit]